US venture capital firms raised $10.3bn during the second quarter of 2015 – the highest quarterly total since the fourth quarter of 2007, according to the National Venture Capital Association (NVCA) – and roughly $2bn of the newly raised cash may be invested in biotechnology companies.
Three biotech-focused VC funds raised almost $1.2bn combined during the second quarter: Clarus Ventures closed a $500m fund in June;...






